Circulation 107:13591365 Yasumura EG, Stilhano RS, Samoto VY, Matsumoto PK, de Carvalho LP, Valero Lapchik VB, Han SW (2012) Treatment of mouse limb ischemia with an integrative hypoxia-responsive vector expressing the vascular endothelial growth factor gene
FDA-approved peptide medications have been studied in large clinical trials, so we have good data supporting their safety
But as a medical professional, I must be clear: The benefits of BPC-157, TB-500, and other unapproved peptides are scientifically unfounded
The number of doses stays the same
Were the Manufacturer: Because we produce in-house, we control purity, potency, and compliance instead of reselling from anonymous overseas labs